Literature DB >> 25164394

An increased alveolar CD4+ CD25+ Foxp3+ T-regulatory cell ratio in acute respiratory distress syndrome is associated with increased 30-day mortality: response to comment by Singer and D'Alessio.

Jürgen Peters1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25164394     DOI: 10.1007/s00134-014-3437-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  3 in total

1.  Comment on Adamzik et al.: An increased alveolar CD4 + CD25 + Foxp3 + T-regulatory cell ratio in acute respiratory distress syndrome is associated with increased 30-day mortality.

Authors:  Benjamin D Singer; Franco R D'Alessio
Journal:  Intensive Care Med       Date:  2014-07-17       Impact factor: 17.440

2.  Hydrocortisone fails to abolish NF-κB1 protein nuclear translocation in deletion allele carriers of the NFKB1 promoter polymorphism (-94ins/delATTG) and is associated with increased 30-day mortality in septic shock.

Authors:  Simon T Schäfer; Sophia Gessner; André Scherag; Katharina Rump; Ulrich H Frey; Winfried Siffert; Astrid M Westendorf; Jörg Steinmann; Jürgen Peters; Michael Adamzik
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

3.  An increased alveolar CD4 + CD25 + Foxp3 + T-regulatory cell ratio in acute respiratory distress syndrome is associated with increased 30-day mortality.

Authors:  Michael Adamzik; Jasmin Broll; Jörg Steinmann; Astrid Maria Westendorf; Irene Rehfeld; Carla Kreissig; Jürgen Peters
Journal:  Intensive Care Med       Date:  2013-08-16       Impact factor: 17.440

  3 in total
  1 in total

1.  PARP-1 Inhibition Repressed Imbalance of Th17 and Treg Cells in Preterm Rats with Intrauterine Infection-Induced Acute Respiratory Distress Syndrome by Reducing the Expression Level of IL-6.

Authors:  Qian Chen; Ensheng Zhang; Chun Wang; Peipei Zhang; Lei Huang
Journal:  J Healthc Eng       Date:  2022-02-12       Impact factor: 2.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.